United Therapeutics wins Delaware ruling that Liquidia infringes treprostinil PH-ILD patent claims

By Public Technologies
  • United Therapeutics won a Delaware federal court ruling that Liquidia’s Yutrepia infringed two claims of its U.S. Patent No. 11,826,327.
  • Decision covered Yutrepia’s PH-ILD use; court rejected Liquidia’s bid to invalidate the claims.
  • Company plans to seek an order directing the FDA to withdraw Yutrepia’s NDA approval, potentially removing it until labeling drops PH-ILD.
  • United Therapeutics also intends to pursue monetary damages for past infringement, including a possible royalty on Yutrepia sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930122219) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.